Fig 2: Suppression of IgE-mediated mast cell activation via inhibition of the MK2-PI3K-Akt axis by resveratrol. (A) Western blot analysis of phospho–Syk, phospho–Gab2, phospho–p65, phospho–p38, phospho–MK2, and phospho–Akt in BMMCs stimulated with antigen for up to 20 min in the presence or absence of 25 µM resveratrol. The level of ß-actin is shown at the bottom as a loading control. (B) Western blot analysis of phospho–Akt in BMMCs stimulated with antigen for up to 20 min in the presence or absence of resveratrol, SB, or PF. The level of ß-actin is shown at the bottom as a loading control. (C) Flow cytometry analysis of CD63 in BMMCs treated with antigen for 40 min in the presence or absence of resveratrol, 10 µM SB, or 10 µM PF (n = 3). (D) ELISA of IL-6, IL-13, and TNF-a in BMMCs treated with antigen for 6 h in the presence or absence of resveratrol, SB, or PF (n = 3). (E) Flow cytometry analysis of CD63 in BMMCs stimulated with antigen for 40 min in the presence or absence of resveratrol, 5 µM LY, or 100 nM WM (n = 3). (F) ELISA of IL-6, IL-13, and TNF-a in BMMCs treated with antigen for 6 h in the presence or absence of resveratrol, LY, or WM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.